• ANEXT(shanghai）Bio-technology Co. formally established.

• the China Pharmaceutical Group - China General Research Institute of Pharmaceutical Industry project started initiating.

• ANEXT had Completed angel round financing.

• ANEXT Jointly signed the "Strategic Cooperation Agreement on Transformation Achievements and Development of New Biological Drugs" with the German National Center for Cellular Therapy in Shanghai.

• Organized the 2021 "PRAISE WOMAN" series of events in Guangdong.

• formally signed the strategic cooperation agreement with Oriental Beauty Valley Enterprise Group Co., Ltd.

• ANEXT(Anhui) Stem Cell Gene Engineering Co. formally established. GMP medical device production base started constructing.

• formally signed the strategic cooperation agreement with Shanghai Jiading District State-owned Assets Management (Group) Co.

• won the "Jingcai Innovation Award" in the Digital China Innovation Competition - Digital Healthcare Track Startup Competition.

• made a strategic investment in Shandong Jiekai Biotechnology Co. CMC and Stem Cell Drug Pilot had started.

• Oriental Beauty Valley Regenerative Medicine College, jointly organized with Oriental Beauty Valley, was officially launched.

• awarded "Top 10 Most Growing Innovative Therapeutic Enterprises" in China's Biomedical Science and Technology Innovation Value List.

• signed with "Oriental Beauty Valley Regenerative Medicine Research Institute" jointly established with Oriental Beauty Valley.

• ANEXT Shanghai Headquarter R&D Center had prepared to established.

• held signing Ceremony of Oriental Beauty Valley Group's Capital Increase in ANEXT. The Pre-A round of financing had complete.

• won the 61st China (Shanghai) International Beauty Expo CIBE Beauty Expo Excellence Gold Award.

• awarded "Top 10 Most Growing Cellular gene therapy Enterprises" in China's Biomedical Science and Technology Innovation Value List.

• Sinopharm's Xinlibang Pharmaceutical Vaccine Pipeline started Strategic Cooperation.

• ANEXT's Investment in Innovative ADC Drug Program Coloplast Passed IPO Hearing.